ESALY News and Press, Eisai Co. Ltd. ADR From 06/24/22

GE Healthcare will become an independent company in the first quarter of 2023. Pharmaceutical diagnostics revenue was $487 million in Q1 2022, up 2.7% QoQ. General Electric Healthcare has one of the largest profit margins in the GE structure. GE is expanding its business by ac...

Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases TOKYO, June 24, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai has signed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglec...

Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal TOKYO, June 22, 2022 - (JCN Newswire) - Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential e...

A group of low cap biotechs are leading a selloff among Alzheimer’s drug developers after Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced on Thursday that their experimental drug for the memory robbing disease did not meet key goals in a mid-stage trial. Developed by the fellow Swiss biote...

Biogen (NASDAQ:BIIB) and Canada-based privately held pharmaceutical company Alectos Therapeutics have reached a license and collaboration agreement to develop and commercialize an experimental therapy called AL01811 for Parkinson’s disease (PD), according to a press release on Monday. ...

Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting TOKYO, June 6, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a ...

Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting TOKYO, June 3, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant ...

EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING PR Newswire NUTLEY, N.J. , June 2, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") announced today a total of seven poster pr...

Clinical-stage pharma company Cassava Sciences (NASDAQ:SAVA) has added more than 15% to reach a two-month high on Tuesday against a recent selloff among biotech stocks and Alzheimer’s drug developers in particular. More than 5.0M Cassava (SAVA) shares have changed hands compared to the...

Eisai Contributes to the Science of Cancer Medicine at ASCO 2022 TOKYO, May 27, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology...